|
- Clinical Research Monitor | Edwards Lifesciences
Aortic stenosis and aortic regurgitation impact millions of people globally, yet it often remains under-diagnosed and under-treated Edwards’ groundbreaking work in transcatheter aortic heart valve replacement (TAVR) pioneered an innovative, life-changing solution for patients by offering heart valve replacement without the need for open heart surgery
- Locations - Edwards Lifesciences
Headquartered in Irvine, California, our teams work together to create a sense of community and are focused on supporting what is best for Edwards and the patient
- Edwards Lifesciences Outlines Growth Strategy at Annual Investor . . .
NEW YORK--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference Edwards enters 2025, its first full year as a purely structural heart company, in a strong position
- Edwards Lifesciences Corp - Study Finds Edwards Lifesciences Port . . .
BERLIN, June 30, 2009 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves, announced that new research demonstrates that using its minimally invasive PORT ACCESS System in mitral valve surgery significantly decreases the length of stay in hospitals and intensive care units (ICU), and improves other outcomes when compared to conventional sternotomy
- Associate Sales Specialist, BD Advanced Patient Monitoring
Becton Dickinson (BD) recently completed the acquisition of the Edwards Critical Care business This position is part of the Critical Care division, and as such will become a part of the BD organization in the future
- Search Jobs | Edwards Lifesciences
COVID Vaccination Requirement Notice Edwards is committed to protecting our vulnerable patients and the healthcare providers who are treating them
- Senior Manager, Sales Training EVOQUE | Edwards Lifesciences
Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a patient’s unmet clinical needs
- Global Locations - Edwards Lifesciences
Learn about early detection, management of conditions, and various treatment options
|
|
|